| Pyrotinib studied in …STUDIED_INderived107 of 107show fewer |
|---|
| → studied in | NCT07836257Phase 2 · not yet recruiting A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05745740Phase 1/Phase 2 · not yet recruiting A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation · 107 trials list this drug (52 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07810634active not recruiting Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07797218Phase 3 · recruiting Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC · 107 trials list this drug (52 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03980054Phase 3 · active not recruiting A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07766772Phase 2 · not yet recruiting Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07708194Phase 1/Phase 2 · recruiting Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure · 107 trials list this drug (52 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07600164Phase 4 · recruiting Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07635342Phase 2 · recruiting Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05582499Phase 2 · recruiting Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy · 107 trials list this drug (52 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Early Stage Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07610720Phase 2 · recruiting Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 107 trials list this drug (52 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05769010Phase 2 · recruiting Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07335081Phase 2 · recruiting ctDNA in HER2+ EBC Neoadjuvant Treatment · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06495541NA · not yet recruiting The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07470203not yet recruiting Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07417241Phase 2 · not yet recruiting SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07393425Phase 2 · recruiting Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer · 107 trials list this drug (52 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340398Phase 2 · recruiting Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04290793Phase 2/Phase 3 · active not recruiting Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04872985Phase 2 · active not recruiting Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer · 107 trials list this drug (52 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04447118Phase 3 · completed Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05751018Phase 2 · recruiting Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer · 107 trials list this drug (52 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05910398Phase 3 · recruiting Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07180082Phase 2 · recruiting Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07179939Phase 2 · not yet recruiting Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04126525Phase 2 · active not recruiting Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04254263Phase 3 · recruiting Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834936Phase 2 · completed A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03588091Phase 3 · completed Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07132242Phase 2 · not yet recruiting SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208410Phase 1/Phase 2 · recruiting A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors · 107 trials list this drug (52 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04571710Phase 2 · withdrawn A Trial of SHR1258 in Patients With Biliary Tract Cancer · 107 trials list this drug (52 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07065435Phase 2 · recruiting RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study · 107 trials list this drug (52 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07053150Phase 2 · not yet recruiting A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors · 107 trials list this drug (52 active) | — | — | Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07019337Phase 2 · not yet recruiting Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06958627Phase 2/Phase 3 · recruiting The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423185Phase 2 · recruiting PLATFORM Study of Precision Medicine for Rare Tumors · 107 trials list this drug (52 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06718933Phase 1/Phase 2 · recruiting Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06754059recruiting Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06718335NA · not yet recruiting Pyrotinib in HER2-positive Early Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 107 trials list this drug (52 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05426486Phase 2/Phase 3 · active not recruiting A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05635487Phase 2 · recruiting A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06217185Phase 4 · recruiting The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06278870Phase 3 · recruiting Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06234137NA · recruiting A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06185400Phase 2 · not yet recruiting RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations · 107 trials list this drug (52 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05328440Phase 2 · unknown Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) · 107 trials list this drug (52 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04367090Phase 1 · completed Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05823623Phase 2 · unknown Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05880927Phase 2 · unknown Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04293276Phase 2 · unknown Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05841381Phase 3 · not yet recruiting Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834764Phase 2 · recruiting Pyrotinib in Women With High-risk in Early Stage Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05806671Phase 2 · unknown Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05764941unknown Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05638594Phase 2 · recruiting Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03772353Phase 1/Phase 2 · unknown Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05252546Phase 1 · completed Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects · 107 trials list this drug (52 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03574402Phase 2 · unknown Phase II Umbrella Study Directed by Next Generation Sequencing · 107 trials list this drug (52 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02973737Phase 3 · unknown A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05577923Phase 2 · unknown Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05560308NA · unknown Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05561686unknown Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04355858Phase 2 · unknown Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429294Phase 2 · unknown Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429684Phase 3 · unknown Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05411276unknown A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2 · 107 trials list this drug (52 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04903652Phase 2 · completed Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04398914Phase 2 · active not recruiting Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05274191Phase 2 · unknown An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors · 107 trials list this drug (52 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05030519unknown A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05255523Phase 2 · unknown Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04929548Phase 4 · not yet recruiting Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111444Phase 2 · unknown Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma · 107 trials list this drug (52 active) | — | — | Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05087706unknown Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS） · 107 trials list this drug (52 active) | — | — | Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05076695Phase 2 · unknown Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04973319Phase 3 · not yet recruiting Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04380012Phase 2 · unknown A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer · 107 trials list this drug (52 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04963595Phase 2 · unknown Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04717531Phase 2 · unknown Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899128unknown Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04756921completed 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04736589Phase 3 · not yet recruiting Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02500199Phase 1 · unknown Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors · 107 trials list this drug (52 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Gastric Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04683445unknown Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04681911Phase 2 · unknown Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04066790Phase 2 · terminated Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04255056Phase 2 · unknown Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04236310Phase 2 · unknown A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. · 107 trials list this drug (52 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04179656Phase 2 · unknown The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor · 107 trials list this drug (52 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04158856Phase 2 · not yet recruiting Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04152057Phase 1/Phase 2 · unknown Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04095390Phase 2 · unknown A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04088110Phase 2 · unknown Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04063462Phase 2 · unknown Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation · 107 trials list this drug (52 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03756064NA · unknown Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer · 107 trials list this drug (52 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03997539Phase 2 · unknown A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03923166Phase 2 · unknown Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03923179Phase 2 · unknown Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03910712Phase 2 · unknown Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03843749NA · unknown Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar. · 107 trials list this drug (52 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01937689Phase 1 · completed Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02422199Phase 1/Phase 2 · unknown A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab · 107 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412383Phase 2 · unknown Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer · 107 trials list this drug (52 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02535507Phase 2 · unknown Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer · 107 trials list this drug (52 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |